These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 7621247

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG, Ethier SP.
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [Abstract] [Full Text] [Related]

  • 4. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
    Alper O, Hacker NF, Cho-Chung YS.
    Oncogene; 1999 Sep 02; 18(35):4999-5004. PubMed ID: 10490835
    [Abstract] [Full Text] [Related]

  • 5. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.
    Cancer Res; 1994 Jul 15; 54(14):3758-65. PubMed ID: 7913407
    [Abstract] [Full Text] [Related]

  • 6. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
    Shawver LK, Mann E, Elliger SS, Dugger TC, Arteaga CL.
    Cancer Res; 1994 Mar 01; 54(5):1367-73. PubMed ID: 7907001
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides.
    Bertram J, Killian M, Brysch W, Schlingensiepen KH, Kneba M.
    Biochem Biophys Res Commun; 1994 Apr 15; 200(1):661-7. PubMed ID: 7909438
    [Abstract] [Full Text] [Related]

  • 9. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
    Tari AM, Hung MC, Li K, Lopez-Berestein G.
    Oncogene; 1999 Feb 11; 18(6):1325-32. PubMed ID: 10022814
    [Abstract] [Full Text] [Related]

  • 10. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG, Schelling ME, Hosick HL.
    Cell Growth Differ; 2000 Mar 11; 11(3):173-83. PubMed ID: 10768865
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
    Roh H, Pippin J, Boswell C, Drebin JA.
    J Surg Res; 1998 Jun 11; 77(1):85-90. PubMed ID: 9698539
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
    Liu J, Spence MJ, Wallace PM, Forcier K, Hellström I, Vestal RE.
    Cell Growth Differ; 1997 Jun 11; 8(6):667-76. PubMed ID: 9186000
    [Abstract] [Full Text] [Related]

  • 15. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 01; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 20. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.
    Kumar R, Mendelsohn J.
    Anticancer Res; 1994 Sep 01; 14(3A):1001-8. PubMed ID: 7915505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.